EGFR and breast cancer: In a cohort of 510 TNBC patients, immunohistochemistry and RNA sequencing revealed that the combined HER3-EGFR score is a more comprehensive prognostic marker than individual HER3 and EGFR scores and high HER3-EGFR score predicts worse breast cancer-specific and distant metastasis-free survival, suppressed apoptosis-inducer ATM activity, activation of EGFR, PARP1, and caspases, and inhibition of p53 and NFκB (154).